Rifampicin clinical trials
Rifampicin is named as an intervention in 19 current clinical trials in our China, France, India, Japan, South Korea, Brazil and Mexico registers. 11 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Bin Cao (2). The most-studied condition is Tuberculous Meningitis. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
What health systems spend on Rifampicin
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
Patient leaflets for Rifampicin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 4 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Rifampicin
19 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Rifampicin in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Rifampicin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci
2026-526149-91-00 · Bacterial Infections and Mycoses
|
Phase 3 | Authorised | Friedrich-Schiller-Universitaet Jena | Germany |
Rifampicin across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
4 single-substance products containing Rifampicin on the HPRA medicines list.
- Rifadin 100 mg/5 ml Oral SuspensionSanofi-Aventis Ireland Limited T/A SANOFI · PA0540/066/004 · Marketed
- Rifadin 150mg CapsulesSanofi-Aventis Ireland Limited T/A SANOFI · PA0540/066/001 · Marketed
- Rifadin 300mg CapsulesSanofi-Aventis Ireland Limited T/A SANOFI · PA0540/066/002 · Marketed
- Rifadin Intravenous 600mg Powder and Solvent for Concentrate for Solution for InfusionSanofi-Aventis Ireland Limited T/A SANOFI · PA0540/066/003 · Marketed
Supply shortages
- EREMFAT 600 mgGermany (BfArM) · Production problem · 19 Oct 2026 to 7 Dec 2026
Conditions studied with Rifampicin
18 conditionsAll 18 conditions
| Condition (as registered) | Trials |
|---|---|
| Tuberculous Meningitis | 2 |
| Mycobacterium Avium Complex Pulmonary Disease | 2 |
| Refractory or Relapsed Solid Tumors | 1 |
| Pulmonary Tuberculosis | 1 |
| Brucellosis | 1 |
| Drug-drug Interaction Study | 1 |
| Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease | 1 |
| Clinical Pharmacology | 1 |
| Breast Cancer | 1 |
| Tuberculosis | 1 |
| Periprosthetic Joint Infection | 1 |
| Healthy Subjects | 1 |
| Lung Infection | 1 |
| MAC Lung Disease | 1 |
| Prosthetic Infection | 1 |
| Infections Joint Prosthetic | 1 |
| Tuberculosis, Pulmonary | 1 |
| Drug Drug Interaction (DDI) | 1 |
Sponsors
lead sponsor per trial+ 3 more sponsors in the trial list above.
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 12 | 7 |
| Clinical trials in France | 3 | 3 |
| Clinical trials in India | 2 | 1 |
| Clinical trials in Japan | 2 | 2 |
| Clinical trials in South Korea | 2 | 0 |
| Clinical trials in Brazil | 1 | 1 |
| Clinical trials in Mexico | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Rifampicin trials
How many clinical trials are testing Rifampicin?
19 current trials in our China, France, India, Japan, South Korea, Brazil and Mexico registers name Rifampicin as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Rifampicin trials recruiting patients?
Yes. 11 of the 19 trials are recruiting: 7 with sites in China, 3 with sites in France, 1 with sites in India, 2 with sites in Japan, 1 with sites in Brazil and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Rifampicin clinical trials?
Bin Cao (2), Indian Council of Medical Research (1), National Institute of Allergy and Infectious Diseases (NIAID) (1) and Qilu Pharmaceutical Co., Ltd (1), among 18 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Rifampicin licensed in Ireland?
Yes. The HPRA medicines list includes 4 single-substance products containing Rifampicin, for example Rifadin 100 mg/5 ml Oral Suspension (Sanofi-Aventis Ireland Limited T/A SANOFI). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Rifampicin shortage?
The registers we track list 1 entry for Rifampicin: 1 German notice. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rifampicin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rifampicin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rifampicin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.